772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)
暂无分享,去创建一个
M. Sznol | I. Puzanov | A. El-Khoueiry | M. Callahan | J. Luke | D. Feltquate | B. Curti | Lizhi Cao | Pushpa Jayaraman | D. Lathers | Dawn M Wilson | Christopher Chen | Li Peng | B. Henick | A. Tolcher | Jenny Che | M. Sharma | Melissa A. Ricker | Sandip Patel | M. Johnson